Examining Data for Osimertinib in EGFR+ Lung Cancer
Heather A. Wakelee, MD, discusses the use of osimertinib as a frontline treatment option for patients with <em>EGFR</em>-positive lung cancer.
Heather A. Wakelee, MD, an associate professor at Stanford University School of Medicine, discusses the use of osimertinib (Tagrisso) as a frontline treatment option for patients withEGFR-positive lung cancer.
In this patient population, there are several first- and second-generation options, according to Wakelee. Third-generation osimertinib was approved by the FDA for this population, as well, with supportive data directly comparing different tyrosine kinase inhibitors in the frontline.
Survivorship Care Promotes Evidence-Based Approaches for Quality of Life and Beyond
March 21st 2025Frank J. Penedo, PhD, explains the challenges of survivorship care for patients with cancer and how he implements programs to support patients’ emotional, physical, and practical needs.
Read More
